arrow
S

Sylvie Giacchetti

Paris-Saclay University
H指数:49
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Association Between Daily Timing of Everolimus and Survival in High-Risk HR+/HER2− Early Breast Cancer: A Sub-Analysis of the UCBG-UNIRAD Trial

依维莫司每日用药时间与高风险HR+/HER2-早期乳腺癌患者生存的关系:UCBG-UNIRAD试验的亚组分析

2025-08-240
PRE
Vinorelbine With or Without Thiotepa for HER2-Negative Metastatic Breast Cancer: A Propensity Score Analysis

长春瑞滨联合或不联合替莫唑胺治疗HER2阴性转移性乳腺癌:一项倾向性评分分析

2025-07-280
OAAI
Differential benefit of adjuvant everolimus according to endocrine therapy backbone in the randomized UNIRAD trial

在随机UNIRAD试验中,根据内分泌治疗基础方案,辅助依维莫司的差异化获益

2025-05-010
OAAI
Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trial
2024-06-010
OAAI
Trajectories and predictors of peripheral neuropathy after neoadjuvant chemotherapy in a prospective cohort of 11,014 patients with early breast cancer
2024-05-020
PRE
Germline and acquired genetic variants and long-term cancer-related fatigue among survivors of early-stage breast cancer (BC)
2024-05-020
PRE
Prognostic value of EndoPredict test in patients with hormone receptorpositive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial
2024-05-010
OAAI
Contraception in breast cancer survivors from the FEERIC case-control study (performed on behalf of the Seintinelles research network)
BREAST
IF7.9
2023-02-013
OAAI
Factors associated with chemotherapy (CT)-related amenorrhea (CRA) and its relationship with quality of life (QOL) in premenopausal women with early breast cancer (BC): Results from the prospective CANTO cohort study
2022-09-012
OA
Pregnancy, fertility concerns and fertility preservation procedures in a national study of French breast cancer survivors
2022-06-019
OAAI
Prognostic value of EndoPredict test in patients screened for UNIRAD, a UCBG randomized, double blind, phase III international trial evaluating the addition of everolimus (EVE) to adjuvant hormone therapy (HT) in women with high risk HR+, HER2-early breast cancer (eBC)
2022-02-150
PRE
Multicenter evaluation of breast cancer patients' satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic
2021-09-2944
OA
Unhealthy behaviors after breast cancer: Capitalizing on a teachable moment to promote lifestyle improvements
CANCER
IF5.1
2021-04-2215
OAAI